146 related articles for article (PubMed ID: 14718627)
1. Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant.
Boname JM; Coleman HM; May JS; Stevenson PG
J Gen Virol; 2004 Jan; 85(Pt 1):131-135. PubMed ID: 14718627
[TBL] [Abstract][Full Text] [Related]
2. A replication-deficient murine gamma-herpesvirus blocked in late viral gene expression can establish latency and elicit protective cellular immunity.
Kayhan B; Yager EJ; Lanzer K; Cookenham T; Jia Q; Wu TT; Woodland DL; Sun R; Blackman MA
J Immunol; 2007 Dec; 179(12):8392-402. PubMed ID: 18056385
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the M2 gene of murine gammaherpesvirus 68 alters splenic latency following intranasal, but not intraperitoneal, inoculation.
Jacoby MA; Virgin HW; Speck SH
J Virol; 2002 Feb; 76(4):1790-801. PubMed ID: 11799175
[TBL] [Abstract][Full Text] [Related]
4. Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73.
Fowler P; Efstathiou S
J Gen Virol; 2004 Mar; 85(Pt 3):609-613. PubMed ID: 14993644
[TBL] [Abstract][Full Text] [Related]
5. Latent antigen vaccination in a model gammaherpesvirus infection.
Usherwood EJ; Ward KA; Blackman MA; Stewart JP; Woodland DL
J Virol; 2001 Sep; 75(17):8283-8. PubMed ID: 11483773
[TBL] [Abstract][Full Text] [Related]
6. The M4 gene of murine gammaherpesvirus 68 modulates latent infection.
Geere HM; Ligertwood Y; Templeton KM; Bennet I; Gangadharan B; Rhind SM; Nash AA; Dutia BM
J Gen Virol; 2006 Apr; 87(Pt 4):803-807. PubMed ID: 16528028
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with recombinant adenoviral vectors expressing murine gammaherpesvirus-68 genes M2 and M3 can reduce latent viral load.
Hoegh-Petersen M; Thomsen AR; Christensen JP; Holst PJ
Vaccine; 2009 Nov; 27(48):6723-30. PubMed ID: 19748577
[TBL] [Abstract][Full Text] [Related]
8. Forced lytic replication impairs host colonization by a latency-deficient mutant of murine gammaherpesvirus-68.
May JS; Coleman HM; Smillie B; Efstathiou S; Stevenson PG
J Gen Virol; 2004 Jan; 85(Pt 1):137-146. PubMed ID: 14718628
[TBL] [Abstract][Full Text] [Related]
9. Effective vaccination against long-term gammaherpesvirus latency.
Tibbetts SA; McClellan JS; Gangappa S; Speck SH; Virgin HW
J Virol; 2003 Feb; 77(4):2522-9. PubMed ID: 12551990
[TBL] [Abstract][Full Text] [Related]
10. Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.
McClellan JS; Tibbetts SA; Gangappa S; Brett KA; Virgin HW
J Virol; 2004 Jul; 78(13):6836-45. PubMed ID: 15194759
[TBL] [Abstract][Full Text] [Related]
11. Alpha/beta interferons regulate murine gammaherpesvirus latent gene expression and reactivation from latency.
Barton ES; Lutzke ML; Rochford R; Virgin HW
J Virol; 2005 Nov; 79(22):14149-60. PubMed ID: 16254350
[TBL] [Abstract][Full Text] [Related]
12. Murine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latency.
Coleman HM; de Lima B; Morton V; Stevenson PG
J Virol; 2003 Feb; 77(4):2410-7. PubMed ID: 12551978
[TBL] [Abstract][Full Text] [Related]
13. The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells.
Herskowitz JH; Jacoby MA; Speck SH
J Virol; 2005 Feb; 79(4):2261-73. PubMed ID: 15681428
[TBL] [Abstract][Full Text] [Related]
14. Mouse strain differences in the chemokine response to acute lung infection with a murine gammaherpesvirus.
Weinberg JB; Lutzke ML; Alfinito R; Rochford R
Viral Immunol; 2004; 17(1):69-77. PubMed ID: 15018663
[TBL] [Abstract][Full Text] [Related]
15. Limited protection against γ-herpesvirus infection by replication-deficient virus particles.
Lawler C; Stevenson PG
J Gen Virol; 2020 Apr; 101(4):420-425. PubMed ID: 31985394
[TBL] [Abstract][Full Text] [Related]
16. Immune evasion by gamma-herpesviruses.
Stevenson PG
Curr Opin Immunol; 2004 Aug; 16(4):456-62. PubMed ID: 15245739
[TBL] [Abstract][Full Text] [Related]
17. Early establishment of gamma-herpesvirus latency: implications for immune control.
Flaño E; Jia Q; Moore J; Woodland DL; Sun R; Blackman MA
J Immunol; 2005 Apr; 174(8):4972-8. PubMed ID: 15814726
[TBL] [Abstract][Full Text] [Related]
18. ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection.
Samreen B; Tao S; Tischer K; Adler H; Drexler I
Front Immunol; 2019; 10():2984. PubMed ID: 31921215
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of murine gammaherpesvirus 68 gene expression following infection of murine cells in culture and in mice.
Rochford R; Lutzke ML; Alfinito RS; Clavo A; Cardin RD
J Virol; 2001 Jun; 75(11):4955-63. PubMed ID: 11333874
[TBL] [Abstract][Full Text] [Related]
20. Absence of splenic latency in murine gammaherpesvirus 68-infected B cell-deficient mice.
Usherwood EJ; Stewart JP; Robertson K; Allen DJ; Nash AA
J Gen Virol; 1996 Nov; 77 ( Pt 11)():2819-25. PubMed ID: 8922476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
